Fairvalue-Calculator Fairvalue-Calculator
EN DE

CodeLab Capital AS (CODE) Fair Value & Analysis

Healthcare · NO · Market cap 40.5M NOK

Pricekr 3.53
Fair Valuekr 1.33
Upside-62.3%
Quality93/100
Evidence: Low Range kr 0.9900 – kr 1.98

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

CodeLab Capital AS (CODE) currently trades at kr 3.53, while our model-based Fair Value estimate is kr 1.33 — implying the stock looks roughly 62.3% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

CodeLab Capital AS provides software development tools in Norway and internationally. The company was formerly known as PatientSky Group AS and changed its name to CodeLab Capital AS in May 2023. CodeLab Capital AS was founded in 2014 and is headquartered in Trondheim, Norway.

Open the full interactive analysis →

Similar stocks

Veeva Systems Inc (VEEV) -37% Pro Medicus Limited (PME) -79% BrightSpring Health Services, Inc (BTSG) -61% Tempus AI, Inc (TEM) -74% HealthEquity, Inc (HQY) -39% M3, Inc (MTHRY) +48%

Frequently asked questions

Is CodeLab Capital AS (CODE) undervalued?
As of Jun 25, 2026, our model estimates a fair value of kr 1.33 versus a price of kr 3.53 — about −62% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CODE?
Our 21-model fair value for CodeLab Capital AS is kr 1.33 (as of Jun 25, 2026), built from audited fundamentals. The current price is kr 3.53.
What is the quality score of CODE?
CodeLab Capital AS has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.